


In the claims:

Please amend the claims as follows:

Q4 1. (Currently amended) A compound of the general formula (I):



wherein

R₁ is hydrogen, C₁₋₄ alkyl, C₃₋₄-alkenyl, C₁₋₄-acyl, C₁₋₄-alkoxycarbonyl, 2-hydroxyethyl, 2-cyanoethyl, tetrahydropyran-2-yl, or a nitrogen protecting group;

R₂ is hydrogen, C₁₋₄-alkyl, hydroxymethyl, C₁₋₄-alkoxymethyl, or fluoromethyl;

R₃ and R₄ independently of each other are hydrogen, halogen, methyl, C₁₋₄-alkyl, aryl, or heteroaryl wherein aryl and heteroaryl residues in turn may be substituted in one or more positions independently of each other by halogen, C₁₋₄-alkyl, C₁₋₄-alkoxy, C₁₋₄-alkylthio, C₁₋₄-alkylsulphonyl, methanesulphonamido, acetyl, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, amino, methylamino, dimethylamino, or acetamido;
or

~~R₃ and R₄ together with the carbon atoms to which they are bound form a 5- or 6-membered aromatic or heteroaromatic ring, which may be substituted in one or more positions by halogen, methyl, methoxy, methylthio, methylsulphonyl, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethylthio, amino, methylamino, dimethylamino or acetamido;~~

a⁴ R₅ and R₆ independently of each other are hydrogen, C₁-C₄-alkoxy-C₂-C₄-alkyl, hydroxy-C₂-C₄-alkyl, C₁-C₆-alkyl, C₂-C₆-acyl, aryl, heteroaryl, aryl-C₁-C₂-alkyl, heteroaryl-C₁-C₂-alkyl, aryl-C₁-C₂-acyl, heteroaryl-C₁-C₂-acyl, and wherein any aryl or heteroaryl, alone or as part of another group, may be independently substituted in one or more positions by C₁₋₄-alkyl, C₁₋₄-alkoxy, C₁₋₄-alkylthio, C₂₋₄-acyl, C₁₋₄-alkylsulphonyl, cyano, nitro, hydroxy, C₂₋₃-alkenyl, C₂₋₃-alkynyl, fluoromethyl, trifluoromethyl, trifluoromethoxy, halogen, dimethylamino, or methylamino; or

R₅ and R₆ together with the nitrogen atom to which they are bound form a saturated heterocyclic ring having 4-7 ring members which ring may contain an additional heteroatom and which may be substituted by methyl, oxo, or hydroxy;

R₇ is hydrogen or a substituent selected from halogen, methyl, methoxy, and ethoxy; and

n = 1 - 3;

and pharmaceutically acceptable salts, ^{n.m.?} solvates, hydrates, geometrical isomers, tautomers, optical isomers, N-oxides or prodrug forms thereof.

2.(Original) The compound according to claim 1, wherein R₁ is hydrogen or methyl.

3. (Original) The compound according to claim 1, wherein R₁ is hydrogen.

4. (Original) The compound according to claim 1, wherein R₂ is hydrogen or methyl.

5.(Currently Amended) The compound according to claim 1, wherein R₃ and R₄ independently are hydrogen, halogen or methyl; ~~or wherein R₃ and R₄ form a ring together with the ring carbons to which they are bound and the ring is benzene, to give quinoxaline, or thiophene, to give thieno[3,4-b]pyrazine, and when the rings are substituted, they are mono or disubstituted.~~

6. (Original) The compound according to claim 1, wherein R₃ and R₄ both are hydrogen.

7. (Original) The compound according to claim 1, wherein R₇ is hydrogen.

8. (Original) The compound according to claim 1, wherein R₇ is hydrogen and the group -CH₂N(R₅)(R₆) is attached to the *meta*-position, relative to the alkylendioxy side-chain, of the phenyl ring.

9. (Original) The compound according to claim 1, wherein R₅ and R₆ together with the nitrogen atom to which they are bound form a ring selected from azetidine, pyrrolidine, piperazine, homopiperazine, morpholine, thiomorpholine, and piperidine.

10. (Original) The compound according to claim 1, wherein n = 1.

11. (Original) The compound according to claim 1, selected from
2-(1-Piperazinyl)-3-{2-[3-(4-morpholinylmethyl)phenoxy]ethoxy}pyrazine;
2-(1-Piperazinyl)-3-{2-[3-(1-pyrrolidinylmethyl)phenoxy]ethoxy}pyrazine;
2-(1-Piperazinyl)-3-{2-[3-(4-methyl-1-piperazinylmethyl)phenoxy]ethoxy}pyrazine;
2-(1-Piperazinyl)-3-{2-[3-{{(2-methoxyethyl)amino}methyl}phenoxy]ethoxy}pyrazine; and
2-(1-Piperazinyl)-3-{2-[3-{{(isopropylamino)methyl}phenoxy]ethoxy}pyrazine and their pharmacologically acceptable salts and solvates.

12. (Original) A pharmaceutical composition comprising a compound according to claim 1 as an active ingredient, together with a pharmacologically and pharmaceutically acceptable carrier.

13. (Original) A method for the prophylaxis or treatment of a serotonin-related disease in a human being or in an animal, which method comprises administering to a subject in need thereof an effective amount of a compound according to claim 1.

14. (Original) The method according to claim 13 wherein said disease is a 5-HT_{2c} receptor-related disease.

15. (Original) The method according to claim 13 wherein said disease is selected from eating disorders, memory disorders, schizophrenia, mood disorders, anxiety disorders, pain, substance abuse, sexual dysfunctions, epilepsy and urinary disorders.

16. (Currently amended) The method according to claim ~~13~~15 wherein the eating disorder is obesity.

17. (Original) A method for modulating 5HT_{2c} receptor functions in a human being or animal, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1.

Claims 18-24 (Withdrawn)
